Background and Aims: Ulcerative colitis patients display increased numbers of circulating proinflammatory monocyte human leukocyte antigen-DR [HLA-DR hi ] monocytes expressing high levels of the gut-homing C-C chemokine receptor 9 [CCR9] and tumour necrosis factor [TNF]-α. The aim of this first-in-human, double-blind, randomised, placebo-controlled trial was to evaluate selective removal of circulating CCR9-expressing monocytes by leukapheresis in patients with moderate to severe ulcerative colitis, with regards to safety, tolerability, and immunological response. 
Introduction

Inflammatory bowel disease [IBD] is divided into the two entities:
Crohn's disease [CD] and ulcerative colitis [UC] . The hallmark of UC is chronic superficial inflammation of the colonic mucosa, due to a disrupted balance between the intestinal immune system and the commensal flora. To date, the immunological pathophysiology behind inflammatory bowel disease remains poorly understood even though multiple genetic and immunological defects have been identified. [1] [2] [3] [4] In addition, several factors such as infections in early life and changes in commensal bacteria may result in susceptibility to chronic intestinal inflammation. [5] [6] [7] When the balance of the immune system is disturbed by genetic predisposition and environmental challenges, activated blood cells enter the intestine, induce inflammation, and attract additional immune cells in a chronic fashion. Patients with active IBD display increased numbers of circulating granulocytes and monocytes, which are assumed to be en route to the inflamed bowel mucosa. [8] [9] [10] [11] Subsequent differentiation of CD14 + monocytes into tumour necrosis factor [TNF]-α producing macrophages upon chemokine-mediated entry into the mucosa fuels the inflammation and contributes to further epithelial disruption and inflammation. 12, 13 A key component for directing circulating pro-inflammatory cells to the target organ is the attraction by integrins and chemokines. Integrins are dimeric cell surface receptors with an α and a β subunit which bind tightly to adhesion molecules on the vascular lining, allowing for arrest and migration across the endothelial cells. In the gut vasculature, the interaction between α4β7 on cells and MAdCAM-1 and VCAM-1 expressed by the endothelium plays a central role for recruitment of leukocytes. 14, 15 Chemokines are small proteins that guide circulating leukocytes to target organs such as the skin or intestinal tract. This migratory homing mechanism is often organ-specific and the chemokines induce chemotaxis by recruiting particular immune cells that express the appropriate G-protein coupled chemokine receptor, thereby accomplishing both tissue-and cell-specific migration. 16 In IBD, cells expressing the gut-homing C-C chemokine receptor 9 [CCR9] are recruited to the mucosa by binding to the C-C chemokine ligand CCL25. [17] [18] [19] The CCR9-CCL25 interaction is very specific and one of the crucial homing mechanisms in this context, and previous animal models have identified its importance in the attraction of leukocytes, especially to the small intestine. [20] [21] [22] [23] In a previous study, we have shown that circulating pro-inflammatory HLA-DR hi expressing CD14 + monocyte subset expresses high levels of CCR9, the gut-homing chemokine receptor. In addition, these activated HLA-DR hi monocytes have an increased capacity to make TNF-α, and their presence in the circulation correlates with clinical activity in IBD patients as seen in our publication. 24 Therefore, we have identified the circulating CCR9 + HLA-DR hi monocyte population as an attractive target for selective leukapheresis [Supplementary Figure 1 , available as Supplementary data at ECCO-JCC online]. In this study, a novel selective leukapheresis column is presented based on high affinity chemokine-chemokine receptor interaction involving CCR9. Biotinylated CCL25, the CCR9 ligand, has been coupled with streptavidin-conjugated Sepharose beads in a column and used for apheresis in a perfusion system connected to the patient. 25 The rationale has been to remove gut-homing CCR9-expressing pro-inflammatory monocytes; 23 patients presenting with flares of UC were included in this double-blinded, placebocontrolled induction trial. Proof of concept, safety, and tolerability of leukapheresis-mediated removal of CCR9-expressing immune cells were investigated.
Materials and Methods
Column device
The column used in this study has been designed for extracorporeal leukapheresis to specifically remove CCR9-expressing immunological cell populations from the circulation. 25 This was achieved by designing a column carrying big-bead streptavidin Sepharose™ matrix [average bead size 200 µm] coupled with GMP-manufactured biotinylated CCL25, TLA Gut™ [ Figure 1A ]. The Sepharose™ distributes the blood homogeneously throughout the column and exposes the attached chemokine to passing cells. Thus, the CCL25-loaded matrix provides a solid support for depleting CCR9 + cells taking advantage of the strong affinity binding between the gut-homing cell receptor, CCR9 and is ligand CCL25 [ Figure 1A and B]. CCR9 -cells pass through the column unaffected and are returned to the patient. Filters on both ends of the column are added to prevent leakage of Sepharose™ particles into the circulation. Toxicity and stability testing has been performed according to ISO standard 10993 for biological evaluation of a medical device. The cubital veins were used for venous access and the patient was connected to the heparinised extracorporeal circuit. Blood was drawn from one arm of the patient through the sterile tubing system by the pump, passed through the column and returned to the patient [ Figure 1B ]. Two column variants were used in the study; one active column containing biotinylated CCL25 with the capacity to specifically bind circulating CCR9-expressing cells, and one placebo column void of CCL25 and containing matrix only.
Patients and study design
The trial design was a randomised, double blinded, placebo-controlled, induction study to evaluate the clinical efficacy, safety, and tolerability as well as immunological effects of this novel leukapheresis treatment in patients presenting with acute flare of moderate to severe UC. This is a first-in-human trial with extension for safety monitoring conducted at one centre, the Department of Gastroenterology, Södersjukhuset, Stockholm, Sweden. The trial was monitored by a contract research organisation [CRO] . A total of 23 UC patients were included in the trial; 14 patients were randomised to active treatment and nine patients to placebo. The randomisation was designed to distribute the patients in a ratio of 3:2 in favour of the active treatment group in blocks of five patients. The reason for favouring the active group was to increase the inclusion rate. For patient demographics at baseline, see Table 1 . The inclusion criteria were age 18 to 75 years and diagnosis of ulcerative colitis of moderate to severe activity [Mayo score 6-11, with stool frequency score of > 1, flexible sigmoidoscopy findings > 1, and minimum extension 15 cm from anus]. Prednisolone ≤ 20 mg daily [stable dose at least 2 weeks, may be tapered] and stable doses of systemic 5-aminosalicylic acid and/or thiopurines were allowed. No ongoing topical treatment was permitted. All patients were naïve to anti-TNF antibodies. Smoking was not allowed, to avoid bias since it is known to dampen the inflammation in UC. 26 Based on theoretical calculation of the depletion of CCR9-expressing monocytes in earlier studies, five consecutive treatment sessions were given to each patient every second day [D] on D1, D3, D5, D7, and D10 [ Figure 1C] . 24, 25 The extracorporeal system was primed with a sterile saline solution with 5000 IE heparin, and a bolus injection with 4000 IE heparin was injected into the circuit at the start of the treatment session. A treatment session was considered complete when ≥ 900 ml-1400 ml of blood had been processed. Due to safety reasons in this first-in-human study with patients experiencing active ulcerative colitis, the treatment was unblinded at visit 6 [D 12 ] after all the clinical assessments including sigmoidoscopy were completed. The unblinding made it possible to offer early active treatment to patients not responding to treatment or progressing in the symptoms.
A baseline disease clinical activity index [full Mayo score including sigmoidoscopy] was calculated from data obtained at the screening visit. 27 See Table 1 Since the primary target of the CCR9-selective depletion was circulating HLA-DR hi pro-inflammatory monocytes, the reduction of these monocytes in the blood was chosen as the primary endpoint. Secondary endpoints were safety, clinical response to the treatment, and change in circulating CCR9-expressing leukocytes. Clinical response was defined as a reduction in Mayo score of ≥ 3 points [at least 30% reduction from baseline]. Clinical remission was defined as Mayo score ≤ 3 due to the short treatment period [12 days], since the patients were not expected to reach below three points in such a short time period. The full analysis set [FAS] was defined as all patients who had been subjected to at least one treatment session and had at least one non-missing post-treatment observation for the primary variable.
All patients in the per protocol analysis set [PPAS] included the FAS patients who also showed sufficient protocol compliance during the treatment phase, e.g. no major protocol deviations, had available data for the primary variable for four or more treatment visits, and were subjected to processing of ≥ 900 ml of blood at four or more treatments. The evaluation is made on D 12 except for patients not 
Procedure
The targeted blood volume to perfuse was set to 1800 ml/treatment session since this is a well-documented volume used in other leukapheresis studies, but the treatment was considered complete when ≥ 900 ml-1400 ml of blood had been processed. 28 To minimise discomfort for the patient, peripheral veins of the antecubital area were used and an 18G plastic cannula introduced. The speed of the perfusion pump was set to 30 ml/min and the maximum treatment time was 1 h.
Immunological analysis
For flow cytometry studies, peripheral blood mononuclear cells [PBMC] were obtained from heparinised whole-blood samples by incubation in hypotonic buffer [160 mM NH 4 Cl, 10 mM Tris-HCl, pH = 7.4] for 15 min. Following washing, cell suspensions were incubated for 15 min in PBS supplemented with 10% human serum to prevent non-specific Fc-receptor binding, followed by washing in PBS supplemented with 2% FBS and 0.05% NaN 3 . In preparation for flow cytometry analysis, cell stainings were carried out using combinations of the following antibody conjugates: CD14-PerCP, HLA-DR-APC-Cy7, CD3-APC, and CCR9-FITC. For defining CCR9-positivity, an isotype-matched control antibody was used. All flow cytometry antibodies were purchased from R&D Systems. 
Statistical analysis
All statistical calculations were performed using SAS System ® v 9.3 [SAS Institute Inc., Cary, NC, USA] except for Mantel´s test [an extension of Fisher's permutation test and Pitman's test; calculated using non-commercial software developed by Professor Anders Odén]. The primary endpoint [the reduction in HLA-DR hi monocyte levels] was evaluated as a regression coefficient. In primary endpoint and Mayo score analyses were carried out without weight adjustment, Mantel's test was used for comparisons between treatment groups. For analyses of post-treatment changes within each group, the Wilcoxon signed rank test was used. When comparing active and placebo groups, adjustment for baseline weight was made using an analysis of covariance in SAS ® with a term for randomised treatment and a covariate for baseline weight. Adjusted mean changes from baseline were extracted for the placebo group and for the active group; the difference in these means provided the treatment effect estimate. ANCOVA [without weight adjustment] was used for comparisons of Mayo subscore changes between active and placebo groups and Mayo score analysis in relation to treatment volume [ Figure 2C ]. The Spearman Figure 2B . A p-value of ≤0.05 was considered statistically significant. 
Ethics statement
Results
Study population
A total of 23 patients were included in the study [ Table 1 ]. Fourteen patients were randomised to active treatment and nine to placebo [ Figure 1C ]. All patients were diagnosed with UC as verified by histopathology and endoscopic examination. The demographics in the active and placebo groups differed with regards to gender and body weight. In the active treatment group, eight out of 14 patients were females [57%] as compared with eight out of nine in the placebo group [89%]. The mean body weight in the active group was 12 kg higher [18%] compared with patients receiving placebo [p = 0.05]. At screening, the majority of patients had inflammatory burden limited to the distal colon. The mean extension of the inflammation was 22 cm for all patients included in the trial. The mean C-reactive protein [2.9 mg/l; CRP] was within normal range at baseline. The full Mayo score at screening was slightly higher in the active treatment group [8.7 compared with 8.1 in the placebo group, No change in CRP was seen after the apheresis treatment. Posttreatment Mayo score ≤ 3 was observed in five out of 14 patients [35.7%] in the active treatment group compared with one out of eight in the placebo group [12.5%; FAS; Figure 3A] . The number of responders [including remitters] in the active treatment group was eight out of 14 patients [57.1%], whereas in the corresponding placebo group three out of eight patients [37. 5%] responded to placebo [ Figure 3B ]. Four patients in the active treatment group did not reach D 12; three of these patients were regarded as treatment failures. One patient received one treatment and showed a reduction in Mayo score from 9 to 3 at evaluation D 5. The patient decided to discontinue treatment due to post-procedural headache (SAE) but was included in the FAS-analysis as a remitter.
Primary endpoint
Secondary endpoints
When comparing the Mayo sub-score components, a significant change was observed with regard to pre-and post-treatment change in rectal bleeding [p = 0.0118; Figure 3C ]. Within the active treatment group, patients demonstrated a significant decrease from 2.4 to 0.9 [p = 0.0005]. Refer to Supplementary Figure 3 for all sub-score comparisons.
Safety
No major safety or tolerability concerns were raised during a total of more than 100 leukapheresis sessions performed. No major discomforts were observed during treatment and the most common adverse effect was headache, which was seen at similar frequencies in the placebo and active treatment groups [39% of the patients]. Two serious adverse events were reported. One event of nausea was classified as severe due to vomiting and headache [active treatment group]. This person responded to therapy but decided not to continue the treatment. Six patients experienced worsening of ulcerative colitis during any period of the trial, but only one of these was regarded as severe due to exacerbation of colitis shortly after inclusion, resulting in withdrawal from the study [ 
Exploratory analyses
Outside the scope of the clinical trial, we conducted a series of post hoc analyses in order to explore biological responses induced by the removal of pro-inflammatory cells by leukapheresis. Considering patients who received active treatment, the five patients achieving clinical remission demonstrated an average reduction of 47% in HLA-DR hi monocytes [ Figure 2A ]. The three clinical responders with a decrease in Mayo score ≥ 3 points but not reaching a final Mayo score of three or less displayed an average decrease of only 5% of circulating HLA-DR hi monocytes. In contrast, the six nonresponders displayed an average increase of almost 15% in HLA-DR hi monocyte levels [ Figure 2A] . Thus, for patients treated with the active column, a correlation between the reduction in circulating HLA-DR hi monocytes and the clinical response as measured by the Mayo score was suggested.
To further explore the relationship between HLA-DR hi monocyte levels with changes in symptoms, alterations in HLA-DR hi monocyte levels were compared with the corresponding variations in Mayo score at visit 6, D 12 [after completing all five sessions] as seen in Figure 2B . At day 12, a correlation between the parallel reductions of HLA-DR hi monocytes and Mayo score was seen in the active treatment group. Interestingly, the three patients in the placebo group responding with a decrease in Mayo score displayed a corresponding down-regulation in HLA-DR hi monocyte levels. Thus, measuring circulating HLA-DR hi monocytes in patients with UC may be a useful biomarker for clinical response.
Dose response
Due to small pore size on the filters on both ends of the column for preventing leakage of Sepharose™ particles into the circulation, pressure was built up during the filtration in some sessions. For safety reasons, these sessions were shortened and a full leukapheresis volume of 1800 ml was not processed. All patients received at least treatment sessions of 900 ml processed blood except in two sessions. The processed blood volume in the active treatment group ranged between 1800 ml and 7650 ml [median = 4980 ml]; and in the placebo group, ranges were 4500 ml to 8250 ml [median = 4860 ml]. The change in Mayo score was correlated with the given leukapheresis volume in order to explore whether a dose-response relationship was present in the active group. In patients receiving a total leukapheresis volume of more than 5500 ml, the average reduction in Mayo score was 5.25 compared with 1.80 in those treated with a total leukapheresis volume of less than 5500 ml, suggesting a dose-response relationship between the total leukapheresis volume and clinical improvement [ Figure 2C ].
Discussion
This is to our knowledge the only first-in-human trial using a specific chemokine-loaded [CCL25] column for the elimination of circulating gut-homing pro-inflammatory immune cells by extracorporal leukapheresis. The study demonstrates that specific leukapheresis treatment targeting CCR9-expressing cells removes circulating proinflammatory HLA-DR hi monocytes and that the elimination of these cells has an effect on the inflammatory symptoms in patients with ulcerative colitis. No major safety or tolerability concerns were raised in this trial.
The chemokine CCL25 is consecutively expressed in the gut and found in epithelial and endothelial cells as well as in the lamina propria. 24, 29 In 2006 14 One argument against inhibiting CCR9 has been the role of parallel migration mechanisms, especially the α4β7-dependent passage though the endothelial lining of the intestine which may compensate for the inhibition of CCR9-dependent migration. 31 This is not of any concern in our study, since the CCL25-based leukapheresis removes the CCR9-expressing immune cells from the circulation instead of inhibiting the migration. CCR9 is used merely for identifying activated and gut-bound immune cells in the circulation in order to extra-corporeally extract them from the blood. By removing the activated cells en route to the inflammatory lesions, the continuous fuelling of the inflammation is attenuated.
Monocytes have been reported to be increased in both Crohn's disease and active ulcerative colitis, and UC patients responding to infliximab show reduced frequency of activated [CD14 + CD86 + ] monocytes in the circulation. 8, 10, 32, 33 In earlier studies we have shown that circulating pro-inflammatory HLA-DR hi monocytes are increased in patients with active intestinal inflammation and correlate with IBD activity. Furthermore, these monocytes produce significant amounts of inflammatory mediators, especially TNF-α, and express high levels of the gut-homing receptor CCR9. 24 Therefore, the down-regulation of these HLA-DR hi monocytes in blood was chosen as primary endpoint for this study. Interestingly, the correlation between these monocytes and clinical activity was seen in all patients regardless of treatment arm [ Figure 2B ].
Clinical response was observed in the active group compared with the placebo group even though the study was short and active treatment was limited to 10 days with evaluation on D 12. In addition, in this pilot study only eight patients were evaluated in the placebo group. The most obvious effects of depleting the circulation of HLA-DR hi monocytes by this selective apheresis were seen in rectal bleeding and stool frequency [ Figure 3C and Supplementary  Figure 3 , available as Supplementary data at ECCO-JCC online]. The observation period is probably too short to detect significant differences in mucosal appearance between active and placebo groups. The lack of effect on CRP levels is probably due to the fact that CRP is not as frequently elevated in UC compared with Crohn's disease. 34 Indeed, the mean CRP level at inclusion was within normal range in the study cohort, making it difficult to draw any conclusions on the effect on CRP by CCR9-specific apheresis.
The idea of extracorporeal extraction of circulating cells is well established in immunological diseases and hyperlipidaemia. 35, 36 There are two apheresis systems available today for IBD, Granulocyte/ Monocyte Apheresis [GMA, Adacolumn®] and Leukocytapheresis [LCAP, Cellsorba®] . GMA is based on a column filled with cellulose acetate beads that bind Fcɣ-receptor expressing immune complexes that are adsorbed onto the beads. 37 A randomised sham-controlled study of active UC did not show significant efficacy in the study cohort, even though a subgroup analysis showed efficacy in severe acute UC. 38 The LCAP consists of nonwoven polyester fibres that filter the blood from leukocytes, including lymphocytes and platelets. The latter system has been subjected to small randomised controlled trials as well as a post-marketing study of 847 patients showing overall clinical remission rate of 68.9% and mucosal healing in 62.5% of the UC patients. 39 In contrast, the CCL25/CCR9-based apheresis uses a gut-specific cellular receptor that is mainly expressed on guthoming immune cells. In addition to being gut-specific, the CCL25/ CCR9 binding has a higher affinity [K D = 8 nM] compared with antibody interaction, allowing for a theoretically highly efficient selective adsorption of all CCR9-positive cells en route to the intestinal inflammation. 25 Arguments may be raised against choosing ulcerative colitis for the study. The first reports identified the CCL25 chemokine in the small intestine of murine models. 21, 40, 41 However, later studies have identified CCL25 in the colon of mouse models as well as in IBD patients, and the chemokine seems to be up-regulated in inflamed colonic mucosa. 24, [42] [43] [44] [45] Moreover, the first CCX282-B trial showed efficacy in Crohn´s patients with extensive colonic disease, thereby establishing a role of CCL25-CCR9 interaction in colonic inflammation.
14 The CCL25-CCR9 axis is probably not the major mucosal recruitment mechanism of monocytes in UC since monocytes express multiple chemokine receptors simultaneously. However, CCR9 expression is induced by inflammation and the increased expression of CCR9 on circulating pro-inflammatory HLA-DR hi monocytes from patients with UC was used as a high-affinity target to selectively identify and eliminate circulating TNF-α producing cells by leukapheresis from the blood, preventing homing to the gut. The main reason for including ulcerative colitis patients in the current trial has been the easily accessible assessment of mucosal inflammation by sigmoidoscopies, since we have monitored the patients with repeated full Mayo scoring, including evaluation of the mucosal inflammation.
No evident major safety or tolerability concerns were raised related to the active treatment. Headache was the most common adverse event in both groups, and two of these reported side effects were regarded as serious since the patients sought medical aid at the emergency department. There was no evidence of increased risk of infections among the included patients. In addition, the accumulated experience of other types of leukapheresis systems in the field of IBD has not yet identified any major concerns regarding acute or long-term safety. 37, 46 This is a small placebo-controlled first-in-human trial with the limitation of only including 23 UC patients. However, the downregulation of the circulating pro-inflammatory HLA-DR hi monocytes paralleling improvement of symptoms observed in the active treatment group is encouraging and calls for further randomised controlled studies in IBD patients.
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